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Objective: The PI-3 kinase-Akt pathway plays a role in cartilage anabolic as well as catabolic processes in
response to activation by insulin-like growth factor-1 (IGF-1) and the pro-inﬂammatory cytokines
interleukin-1b (IL-1b) and oncostatin M (OSM). The goal of this study was to determine how PI-3 kinase-
Akt signaling regulates these seemingly opposing functions.
Design: Monolayer cultures of primary human articular chondrocytes were treated with IGF-1, IL-1b,
OSM, or the combination of IL-1b and OSM in time course experiments. Activation of signaling proteins
and MMP production were measured by immunoblotting. Cells were pre-treated with chemical in-
hibitors to block mitogen activated protein (MAP) kinases, PI-3 kinase, or JAK/STAT pathway activation.
Constitutively active Akt1 and Akt3 were expressed to study stimulus-independent activation of Akt.
Results: IGF-1, OSM, and the combination of IL-1b and OSM but not IL-1b alone, stimulated phosphor-
ylation of Akt which was sustained longer with IGF-1. IL-1b plus OSM, but not IGF-1, increased chon-
drocyte MMP-13 production which was inhibited with either a general PI-3 kinase inhibitor or speciﬁc
inhibition of the PI-3 kinase-g isoform. Akt1 or Akt3 activity alone was not sufﬁcient to increase pro-
duction of MMP-13. IL-1b/OSM induced MMP-13 production required activation of the MAP kinases, JNK
and p38, as well as the JAK-STAT pathway which were activated by IL-1b plus OSM but not by IGF-1.
Conclusions: The chondrocyte integrates signals from the PI-3 kinase-Akt pathway with signals from
MAP kinases and the JAK-STAT pathway to allow for a differential response to a pro-anabolic (IGF-1) and
a pro-catabolic (IL-1b plus OSM) stimulus.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The activity of intracellular signaling pathways in chondrocytes
is regulated by soluble mediators and by changes in the extracel-
lular matrix1,2. Understanding speciﬁc signaling pathways that play
a role in osteoarthritis (OA) is of interest since these pathways could
serve as therapeutic targets. Major pathways that have been shown
to be active in OA chondrocytes include the mitogen activated
protein (MAP) kinase family, the Wnts, Smads, the JAK-STAT
pathway, toll-like receptor pathways, and the NF-kB pathway1,3.
These pathways mediate both anabolic and catabolic functions in
cartilage and likely work in concert to determine the overall bal-
ance of matrix synthesis and degradation.R.F. Loeser, Thurston Arthritis
hurston Building, CB #7280,
42; Fax: 1-(919)-966-1739.
Loeser).
ternational. Published by Elsevier LThere is some controversy over the potential role of the chon-
drocyte PI-3 kinase-Akt pathway in OA. Stimulation of this pathway
by insulin-like growth factor 1 (IGF-1) has been shown to promote
chondrocyte survival as well as proteoglycan and collagen syn-
thesis4e6. However, other studies have shown that the PI-3 kinase-
Akt pathway is also activated by inﬂammatory cytokines, such as
interleukin-1b (IL-1b) and oncostatin M (OSM), resulting in
increased production of MMPs, including the collagenase MMP-13,
resulting in cartilage matrix loss7e9. Additionally, Akt isoforms 1
and 3 have been shown to be necessary for the IL-1b/OSM stimu-
latedMMP-13 production7. These ﬁndings describing the role of the
PI-3 kinase-Akt pathway in MMP-13 production have led to the
suggestion that this pathway would be an effective target in the
treatment of OA10.
In order to better understand the potential role of the PI-3 ki-
nase-Akt pathway in regulating anabolic and catabolic processes in
cartilage, we compared chondrocyte signaling in response to
stimulation with the anabolic factor IGF-1 and the catabolictd. All rights reserved.
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the PI-3 kinase-Akt pathway to promote cell survival and matrix
synthesis2,3. IL-1b increases MMP production through activation of
the MAP kinase pathways (ERK, JNK, and p38)11. OSM, a member of
the IL-6 family, increasesMMP production through activation of the
JAK/STAT pathway12. The combination of IL-1b and OSM is a more
potent stimulus of MMP production and cartilage matrix destruc-
tion than either cytokine alone and thought to be relevant to pro-
motion of cartilage loss in arthritis7,13.
The response of cells to growth factors and cytokines most often
depends on integration of multiple signals that are generated in a
time dependent fashion and are subject to positive and negative
feedback loops. Here, we focused on the time dependent activation
of key nodes in the IGF-1, IL-1b, and OSM pathways to examine how
these stimuli, which share activation of the PI-3 kinase-Akt
pathway, result in either pro-anabolic activity, in the case of IGF-1,
or pro-catabolic activity, in the case of IL-1b and OSM. We conﬁrm
previously published results that both IGF-1 treatment and IL-1b/
OSM co-treatment result in Akt phosphorylation, and inhibition of
PI-3 kinase blocks IL-1b/OSM stimulated MMP-13 production.
Additionally, we show that active Akt by itself is not sufﬁcient for
MMP-13 production and that the difference between IGF-1 and IL-
1b/OSM in stimulation ofMMP-13 is due to differential activation of
MAP kinases and STAT3. These ﬁndings suggest that MAP kinase or
JAK-STAT pathways would be more appropriate as a therapeutic
target given the pro-anabolic and cell survival role of Akt.Experimental
Reagents
Chemical inhibitors were purchased from Calbiochem
(LY294002, PD98059, SB203580), Sigma (SP600125), and Sell-
eckBiochem (A66, TGX-221, CAL-101, AS-252424, Ruxolitinib). The
doses used and speciﬁc targets for each inhibitor are summarized in
Table I. Recombinant proteins were purchased from Austral Bio-
logical (IGF-1) and R&D Systems (IL-1b, OSM, IL-6, sIL-6R). Anti-
bodies were purchased from Cell Signaling Technology (p-Akt S473,
T-Akt, p-ERK T202/Y204, T-ERK, p-JNK T183/Y185, T-JNK, p-p38
T180/Y182, T-p38), Santa Cruz Biotechnology (p-STAT3 Y705, T-
STAT3), and Abcam (MMP-13, MMP-2).Chondrocyte isolation and cell culture
Chondrocytes were isolated from normal human ankle (talar) or
knee cartilage obtained from tissue donors or osteoarthritic knee
cartilage removed during joint replacement surgery. Normal donor
tissue was obtained from deceased tissue donors through the Gift
of Hope Organ and Tissue Donor Network (Elmhurst, IL) and Rush
University Medical Center (Chicago, IL). OA tissue was removed
from the joint at time of knee replacement surgery at Wake ForestTable I
Summary of inhibitors used in this study
Inhibitor IC50 Dose (mM) Inhibitor target
LY294002 1.4 mM 5 pan-PI-3 kinase
A66 32 nM 10 PI-3 kinase-a
TGX-101 10 nM 10 PI-3 kinase-b
AS-252424 33 nM 10 PI-3 kinase-g
CAL-101 65 nM 10 PI-3 kinase-d
PD98059 2 mM 30 MEK (ERK)
SP600125 40 nM 20 JNK
SB203580 0.3e0.5 mM 10 p38
Ruxolitinib 3.3/2.8 nM 10 JAK1/2 (STAT3)Baptist Health (Winston-Salem, NC). Human tissue use was
approved by the Institutional Review Boards at Rush University,
Wake Forest University School of Medicine and the University of
North Carolina at Chapel Hill. Brieﬂy, the cartilage was dissected
away from the subchondral bone and digested in Pronase (Calbio-
chem) for 1 h at 37C followed by overnight digestion in Collage-
nase P (Roche Diagnostics) at 37C. Cells were cultured in high
density monolayers with 10% serum in D-MEMmedia (Gibco) until
conﬂuent and then made serum-free overnight before treatment.
Cells were treated with 100 or 50 ng/ml IGF-1 (lower dose used for
PI-3 kinase isoform inhibition studies), 0.2 or 10 ng/ml IL-1b (lower
dose used in experiments in Fig. 3, but no difference was seen with
high dose of IL-1b in combination with OSM, so 10 ng/ml was used
in all other experiments), or 10 ng/ml OSM.
Lentivirus infection
Akt1 lentiviral constructs were kindly provided by Dr. Michael
Robinson (Children's Hospital of Philadelphia), and details of the
preparation of the lentivirus were previously published by our
group5. Chondrocytes were infected with lentivirus within 72 h of
plating. The lentivirus (25,000 viral particles/ml) was diluted in 10%
serummedia containing 8 mg/ml Polybrene and incubated at 37C.
The media containing lentivirus and Polybrene was replaced after
24 h. Forty-eight hours post-infection, cells were made serum-free
for 6 h and then co-stimulated with 10 ng/ml IL-1b and 10 ng/ml
OSM overnight.
Nucleofection
Wild-type (pCMV5. HA PKBg) and dominant negative (pCMV5.
HA PKBg T305A/S472A) Akt3 plasmids were kindly provided by
Brian Hemmings (Friedrich Miescher Institute, Switzerland).
Constitutively active Akt3 plasmid (1236 pcDNA3 Myr HA Akt3)
was purchased from Addgene (plasmid #9017).
After isolation and overnight digestion, chondrocytes were
plated and allowed to recover for 48e72 h. Cells were then incu-
bated for 3 h in collagenase and pronase together at 37C to digest
adhesion proteins and lift the cells from the plate. The cells were
rinsed once in 1 Dulbecco's phosphate buffered saline (DPBS,
Lonza), and then resuspended in Human Chondrocyte Nucleofector
Solution (Lonza) at a density of 1  106 cells/100 mL solution. After
combining 100 mL cell solution with 2 mg of appropriate DNA
plasmid, the cells were transferred to an Amaxa cuvette and placed
in the Amaxa Nucleofector II. Following nucleofection, cells were
placed in 20% serum media and plated in Poly-L-lysine (Sigma)
coated tissue culture plates. After overnight incubation in 20%
serum media to allow recovery and to promote adherence of
nucleofected cells, the media was changed to 10% serum until cells
were serum-starved prior to treatment.
Immunoblotting
Following treatment, high density chondrocyte monolayers
were rinsed twice with 1 DPBS and lysed for 30 min in lysis buffer
containing 20 mM TriseHCl, 150 mM NaCl, 1 mM Na2EDTA, 1 mM
EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM b-glycer-
ophosphate, 1 mM Na3VO4, 1 mg/ml leupeptin (Cell Signaling
Technology) with phenylmethanesulfonyl ﬂuoride (PMSF, Sigma)
and Phosphatase inhibitor cocktail 2 (Sigma). The cell lysate was
centrifuged for 10 min at 13,000 rpm to remove the insoluble
fraction. The protein content of the soluble fraction was quantiﬁed
using the Pierce Micro BCA kit (Thermo Scientiﬁc). Approximately
10 mg protein/sample were combined with 2 Laemmli Sample
Buffer (Bio-Rad) containing 5% b-mercaptoethanol, boiled for
Fig. 1. Time course of chondrocyte signaling activated in response to IGF-1, IL-1b, and OSM. Normal human chondrocytes were stimulated with IGF (100 ng/ml), IL-1b (10 ng/
ml), OSM (10 ng/ml), or IL-1b and OSM together (10 ng/ml each) for increasing time points (5e60 min). Total cell lysates were immunoblotted for phosphorylated signaling kinases;
total kinase blots are shown as loading controls. Representative blots are shown from three independent experiments performed using cells from three different tissue donors.
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The protein was transferred to Whatman nitrocellulose membrane
for 90 min at 120 V. Membranes were blocked for 60 min in 5%
blocking buffer (Bio-Rad) and then incubated with the primary
antibody overnight at 4C. Following primary antibody incubation,
membranes were rinsed three times in TBST, incubated with HRP-Fig. 2. Densitometric analysis of time course of chondrocyte signaling activated in respo
to the total kinase loading control and shown as fold-change from untreated control. Dat
isolated from three different normal tissue donors.tagged secondary antibody (Cell Signaling Technology) for 60 min,
and rinsed three times in TBST. Blots were developed using Amer-
sham ECL reagent and visualized. Protein kinase phosphorylation
was measured at indicated time points by immunoblotting cell
lysates with phospho-speciﬁc antibodies. Blots were stripped and
reprobed with antibodies to the total protein as a loading control.nse to IGF-1, IL-1b, and OSM. The signal of the phosphorylated kinase was normalized
a are shown as the average of three independent experiments performed using cells
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SDS-PAGE gels and used for immunoblotting for MMP-13. Blots
were stripped and probed for MMP-2. The levels of MMP-2 were
not altered by the stimuli or inhibitors tested and so were used as a
loading control. Immunoblots were quantiﬁed by densitometry
using ImageJ software.
RT2-qPCR
Following overnight treatment of chondrocytes, the cells were
rinsed twice and then lysed in Trizol (Invitrogen). RNAwas isolated
from the cell lysate using the standard Trizol isolate protocol.
Brieﬂy, chloroform was added to the Trizol lysate, and the samples
were centrifuged to separate phases. The RNA-containing aqueous
phase was transferred to a new tube, and isopropanol was added to
precipitate the RNA. The RNA pellets were washed once with 70%
ethanol, and the RNA was quantiﬁed using the UV/VIS spectro-
photometer. The reverse transcription reaction was performed us-
ing 2 mg RNA/sample. RT enzymes and reagents were purchased
from Promega. RT2-qPCR was performed using SybrGreen Master
Mix and gene-speciﬁc oligos purchased from Qiagen. Each sample
was assayed in three technical replicates.
ELISA
MMP-13 was quantiﬁed in conditioned media using the MMP-
13 solid-phase ELISA kit from R&D systems. Samples were diluted
in Calibrator Diluent (included in kit) and analyzed following the
protocol included in the kit. Each sample was assayed in two
technical replicates. MMP-13 content per sample was calculated
from the standard curve, corrected for the dilution factor, and then
normalized to total protein measured in the cell lysate from each
sample.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 6
(GraphPad Software, Inc.). Densitometry, qPCR, and ELISA data from
at least three independent experiments, each performed using cells
from a unique donor (n for each set of experiments is noted in the
ﬁgure legend where n ¼ the number of independent experiments),
were analyzed by one-way analysis of variance (ANOVA), followed
by Tukey's Honest Signiﬁcant Difference (HSD) post-hoc analysis.
Data are presented graphically as individual points, each repre-
senting an independent experiment with the mean for each con-
dition. In the ﬁgure legends the mean ± standard deviation are
provided.Fig. 3. PI-3K, MAPK, and STAT inhibition block IL-1b/OSM induced MMP-13 pro-
duction. A. Normal chondrocytes were pre-treated with 5 mM LY294002, followed by
30 min stimulation (p-Akt blot) or overnight stimulation (MMP-13 blot). Representa-
tive blots are shown (n ¼ 3 independent experiments using cells from three different
tissue donors). MMP-2 is used as a loading control for MMP-13, and total Akt is shown
as a loading control for p-Akt. Strong p-Akt in the IGF-1 stimulated cells reduces the
ability of the total antibody to recognize Akt. B. Chondrocytes were pre-treated with
inhibitors for 30 min and then stimulated with IL-1b/OSM overnight. Conditioned
media was collected and immunoblotted for MMP-13. MMP-2 was used as a loading
control. C. Densitometric analysis of immunoblots from independent experiments in B
(n ¼ 6 independent experiments with cells from six unique tissue donors, controls and
MAPK inhibitors; n ¼ 3 independent experiments using cells from three unique tissue
donors, Ruxolitinib). Data are presented as mean ± SD. Because human donors produce
variable levels of MMP-13 in response to IL-1b/OSM, densitometry data are normalized
to IL-1b/OSM and shown as percent inhibition from the positive control. Treatment
(mean ± SD): Control (13.23 ± 10.96); IL-1b/OSM (100.0 ± 0.0); PD þ IL-1b/OSM
(43.13 ± 22.99); SP þ IL-1b/OSM (41.18 ± 24.71); SB þ IL-1b/OSM (20.07 ± 16.66);
Rux þ IL-1b/OSM (10.67 ± 5.71). *¼P < 0.0001.
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Activation of PI-3 kinase and MAPK signaling pathways by IL-1b,
OSM, and IGF-1 is time- and stimulus-dependent
The downstream effects of cell signaling are dependent on the
time required to activate a particular pathway as well as the level of
activation and the longevity of the signal. We used a time course
analysis to directly compare the anabolic factor IGF-1 with the
catabolic factors IL-1b and OSM to examine similarities and dif-
ferences in the response. Primary articular chondrocytes were
treated with IGF-1, IL-1b, OSM, or the combination of IL-1b and
OSM at increasing time points from ﬁve to 60 min and relevant
signaling proteins were evaluated for phosphorylation status
which, for the chosen proteins, correlates with activation. Repre-
sentative immunoblots are shown in Fig. 1 and densitometric re-
sults showing the averages from three independent donors are
shown in Fig. 2 to illustrate the different patterns in the responses
of each signaling protein to a particular stimulus.
The anabolic stimulus IGF-1 at 100 ng/ml stimulated Akt
phosphorylation which was detectable at 5 min and sustained out
to 60 min. IGF treatment resulted in weak and transient ERK
phosphorylation that peaked at 10min andwas not detectable after
15 min. IGF treatment did not result in detectable phosphorylation
of the JNK or p38 MAP kinases or STAT3.
IL-1b alone at 10 ng/ml did not stimulate detectable Akt or
STAT3 phosphorylation at any of the time points examined. Higher
doses of IL-1b (up to 1 mg/ml) were also tested and did not stimulate
detectable Akt phosphorylation (data not shown). IL-1b stimulated
phosphorylation of ERK and JNK, with a slight increase in phos-
phorylation at 5 min followed by peak phosphorylation between 10
and 30 min and a decrease in phosphorylation at 60 min. IL-1b
stimulated phosphorylation of p38 at 5 min, followed bymaximum
phosphorylation from 10 to 15 min with little phosphorylation
noted at 60 min.
OSM alone at 10 ng/ml stimulated phosphorylation of Akt at
5e15 min that decreased at 30 min and was undetectable by
60 min. OSM stimulated strong ERK phosphorylation at 5 min that
was sustained out to 30 min but not detectable at 60 min. OSM did
not stimulate detectable JNK phosphorylation and stimulated
weaker phosphorylation of p38 than IL-1b. OSM also stimulated
strong phosphorylation of STAT3 at 5 min which was sustained out
to 30 min and began to decrease at 60 min. The strong stimulation
of p-STAT3 by OSM is expected since OSM is a member of the IL-6
family of cytokines, and IL-6 is a strong stimulator of the JAK/STAT
pathway12.
The combination of IL-1b and OSM stimulated transient phos-
phorylation of Akt that was slightly stronger than the OSM-induced
phosphorylation of Akt; Akt phosphorylation began to decrease at
30 min and was not detectable at 60 min. IL-1b/OSM stimulated
ERK phosphorylation from 5 to 30 min to a level similar to IL-1b
alone or OSM alone. IL-1b/OSM stimulated JNK phosphorylation
from 10 to 30 min (similar to IL-1b alone), and the phosphorylation
signal was not detectable at 60 min. IL-1b/OSM stimulated phos-
phorylation of p38 from 5 to 30 min. IL-1b/OSM induced strong
phosphorylation of STAT3 at 5 min, similar to OSM alone, that was
sustained out to 30 min and began to decrease at 60 min.
PI-3 kinase inhibition blocks IL-1b/OSM stimulation of Akt
phosphorylation and MMP-13 production
We used the general PI-3 kinase inhibitor LY294002 to
determine if inhibition of PI-3 kinase, which is upstream of Akt,
would block MMP-13 production. Primary human articular
chondrocytes (both normal and OA, data is shown for normalcells) were treated with IGF-1 or cytokines (with or without
LY294002) overnight for measurement of MMP levels in condi-
tioned media or for 30 min for measurement of Akt phosphory-
lation. In these experiments, we also examined IL-6 as a stimulus.
IGF-1 and the low dose of IL-1b (0.02 ng/ml) were not sufﬁcient
to increase MMP-13 while OSM and IL-6 did increase MMP-13
which was greatest with OSM [Fig. 3(A)]. Levels of MMP-13 in
the conditioned media did not correlate with levels of Akt
phosphorylation in cell lysates. Akt phosphorylation was stron-
gest with IGF-1 and not detectable with IL-6. However, PI-3 ki-
nase activity was required for the IL-1/OSM mediated increase in
MMP-13 since LY294002 blocked MMP-13 production. Inhibition
of PI-3 kinase by LY294002 had a similar effect on Akt phos-
phorylation and MMP-13 production in OA chondrocytes as in
normal cells (data not shown).
MAP kinase and JAK1/2 inhibition block IL-1b/OSM stimulated
MMP-13 production
The disconnect between MMP-13 production and Akt phos-
phorylation in response to IGF-1 and the cytokines suggests that,
although PI-3 kinase activation is required for IL-1b/OSM signaling
that results in MMP-13 production, additional signals are also
necessary. Since IL-1b/OSM treatment also activates MAP kinase
and the JAK/STAT pathway in chondrocytes, we tested the ability of
MAP kinase and a JAK inhibitor to block the IL-1b/OSM stimulation
of MMP-13. Speciﬁc inhibition of ERK, JNK, p38, or JAK1/2 all
signiﬁcantly reduced the amount of IL-1b/OSM stimulated MMP-13
with the greatest reduction noted after inhibition of either p38 or
JAK1/2 [Fig. 3(B) and (C)]. Inhibition of JAK1/2 blocked IL-1b/OSM
mediated Akt and STAT3 phosphorylation but did not affect IGF-1
mediated Akt phosphorylation. JAK1/2 inhibition also did not
affect IL-1b/OSM or IGF-1 mediated ERK, JNK, or p38 phosphory-
lation [Fig. 3(D)].
Activity of Akt isoforms 1 and 3 alone is not sufﬁcient to stimulate
MMP-13 production
In order to further determine the role of Akt activation in
chondrocyte MMP-13 production, we utilized a lentivirus
construct to over-express wild type or constitutively active Akt1,
with or without IL-1/OSM stimulation, and examined MMP-13
production. We had previously shown that chondrocytes trans-
duced with this construct had a marked increase in proteoglycan
and collagen synthesis as well as expression of type II procollagen
and Sox-95. The overexpression of WT-Akt1 or CA-Akt1 was not
sufﬁcient to stimulate MMP-13 production without IL-1b/OSM and
did not promote a further increase in MMP-13 levels in cells also
treated with IL-1/OSM [Fig. 4(A)]. We also tested expression of a
dominant negative Akt1 construct but found that the high levels of
over-expression needed to compete with endogenous Akt1
resulted in signiﬁcant cell death (measured by LDH release) such
that we could not interpret effects on MMP-13 production (results
not shown).
In addition to Akt1, the Akt3 isoform has also been implicated
in chondrocyte MMP-13 production7. We therefore utilized DNA
plasmids to over-express wild type, constitutively active, and
dominant negative Akt3. The activity of Akt3 alone was not suf-
ﬁcient to increase MMP-13 production, and the amount of MMP-
13 stimulated by IL-1b/OSM was not signiﬁcantly different when
WT-, CA- or DN-Akt3 were over-expressed compared to the GFP
control [Fig. 4(B)]. Unlike our previous ﬁndings with constitu-
tively active Akt114, expression of CA-Akt3 did not signiﬁcantly
affect collagen II expression or proteoglycan synthesis (data not
shown).
Fig. 4. Over-expression of Akt1 or Akt3 has no effect on IL-1b/OSM induced MMP-
13 production. A. Wild type (WT) and constitutively active (CA)-Akt1 were over-
expressed in normal chondrocytes, followed by treatment with IL-1b/OSM. Akt 1
constructs contain a hemagglutinin (HA) expression tag, so the HA blot of total lysates
is shown to conﬁrm expression of constructs. Representative blots are shown (n ¼ 3
independent experiments using cells from three unique tissue donors). B. WT, CA, and
dominant negative (DN)-Akt3 were over-expressed in normal chondrocytes, followed
by treatment with IL-1b/OSM. Representative blots are shown (n ¼ 3 independent
experiments using cells from three unique tissue donors). MMP-2 is shown as loading
control for conditioned media.
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Multiple isoforms of PI-3 kinase can be expressed in chon-
drocytes, and so we determined if a speciﬁc PI-3 kinase isoform
mediated the effects on MMP-13 production in chondrocytes
treated with IL-1b and OSM. We ﬁrst investigated the baseline
mRNA expression of these isoforms in chondrocytes and found
that PI-3 kinase-a and PI-3 kinase-b were the most highly
expressed in chondrocytes. PI-3 kinase-g and PI-3 kinase-d were
also expressed, but at lower baseline levels than the a and b iso-
forms [Fig. 5(A)].
We next tested chemical inhibitors speciﬁc to each PI-3 kinase
isoform. Because the PI-3 kinase-Akt pathway is essential for
chondrocyte survival, we conﬁrmed that overnight treatment of
chondrocytes with these inhibitors at 10 mM did not result in
signiﬁcant cell death (data not shown). Pre-treatment of chon-
drocytes with the inhibitors followed by IGF-1 or IL-1b/OSM
stimulation partially inhibited phosphorylation of Akt [Fig. 5(B)].
The 5 mM dose of the general PI-3 kinase inhibitor LY294002
tested here was not sufﬁcient to completely block the Akt phos-
phorylation stimulated by IGF-1 while it did inhibit IL-1b/OSM
stimulation of Akt phosphorylation. Previous studies from our
group have shown that higher doses of LY294002 (up to 25 mM)
are required to inhibit IGF-1 mediated Akt phosphorylation, but
the lower dose was used in the present study since it was sufﬁ-
cient to block MMP-13 production in response to IL-1b/OSM and
would be more directly comparable to the doses of isoform spe-
ciﬁc inhibitors4.
We examined the effect of the inhibitors on IL-1b/OSM stimu-
lation of MMP-13 production and found that the inhibitor of PI-3
kinase-g, AS-252424, reduced the level of IL-1b/OSM stimulated
MMP-13 to that seen with the general inhibitor LY294002
[Fig. 5(C)]. Inhibition of PI-3 kinase-b with TGX-221 partially
inhibited MMP-13 production while the PI-3 kinase-a anded inhibitors were the least effective. The inhibitors were further
tested using an MMP-13 ELISA which is more quantitative than
immunoblotting. The only statistically signiﬁcant inhibition was
seen with the general inhibitor LY294002 and the PI-3 kinase-g
inhibitor AS-252424 [Fig. 5(D)].
Discussion
Cells such as chondrocytes utilize a complex network of
signaling pathways to integrate and appropriately respond to
multiple cues in their immediate environment. Diverse stimuli,
sometimes even those that mediate opposing functions, can share
common signaling proteins and components of particular path-
ways. The cellular response to such stimuli is determined not by the
activity of a single protein or pathway but rather by the integration
of multiple signals inﬂuenced by both timing and location of the
signals within the cell. Here we show that the divergent responses
mediated by an anabolic factor, IGF-1, that stimulates cartilage
matrix synthesis, and the combination of the catabolic factors IL-1b
and OSM, that stimulate cartilage matrix breakdown, share acti-
vation of the PI-3 kinase-Akt pathway. The differences among the
stimuli which contribute to the divergent responses included the
more sustained phosphorylation of Akt and transient phosphory-
lation of ERK in response to IGF-1 and the additional activation of
JNK, p38, and STAT3 by IL-1b and OSM.
The effects of IGF-1, IL-1b, and OSM on chondrocyte signaling
have been investigated independently but have not been directly
compared5,7. The ﬁnding that inhibition of PI-3 kinase blocks the
increase in MMP-13 is consistent with previous studies7,13. It had
also been shown that siRNA knock-down of Akt1 or Akt3 inhibits
the IL-1b/OSM stimulated MMP-13 production indicating that they
are also required for the increase in MMP-13 in response to IL-1b/
OSM7. Our ﬁnding that expression of constitutively active Akt1 or
Akt3 was not sufﬁcient to increase MMP-13 production shows that
although these signaling proteins may be required for the effect of
IL-1b/OSM, they are not sufﬁcient by themselves, suggesting
additional signaling pathways must also be required.
IL-1b is well known to activate MAP kinase signaling, and OSM
can activate the JAK-STAT pathway11,12. The ability of the combi-
nation of IL-1b and OSM to stimulate chondrocyte MMP-13 pro-
ductionwas most dependent on p38 and JAK-STAT activity. The lack
of appreciable p38 or STAT3 phosphorylation in response to IGF-1
can explain in part why IGF-1 does not stimulate MMP-13 pro-
duction despite the strong activation of the PI-3 kinase-Akt
pathway.
We also examined the role of speciﬁc PI-3 kinase isoforms in
MMP-13 production stimulated by IL-1b/OSM. The LY294002
compound that blocked MMP-13 production is very commonly
used as a PI-3 kinase inhibitor but is not isoform speciﬁc. The
most highly expressed isoforms at the RNA level were PI-3 ki-
nase-a and eb followed by PI-3 kinase-d with little PI-3 kinase-g.
Only inhibition of the g isoform completely blocked MMP-13
production to the level of LY294002. It is possible that the more
highly expressed isoforms were less susceptible to the inhibitors
at the doses used, although all of the inhibitors, except A66 for PI-
3 kinase-a, had at least a partial effect suggesting there could
be some redundancy among the isoforms. Further studies could
test knock-down of speciﬁc isoforms to conﬁrm the inhibitor
results.
Key nodes in the signaling pathways that are activated by IGF-1,
IL-1b, and OSM are shown in Fig. 6 demonstrating points of overlap
and divergence. Previous studies have documented the involve-
ment of individual pathways, such as the IRS-1-PI- kinase-Akt
pathway that mediates proteoglycan and collagen production in
response to IGF-1 and the MEK-ERK pathway which is inhibitory4,5.
Fig. 5. Inhibition of PI-3K-g signiﬁcantly reduces IL-1b/OSM induced MMP-13 production. A. Baseline mRNA expression of PI-3K isoforms in chondrocytes from ﬁve normal
donors (results are presented as individual data points with the mean indicated by the horizontal line). Expression level (mean ± SD): TBP (1.00 ± 0.0); PI-3K-a (3.84 ± 2.56); PI-3K-b
(3.97 ± 0.42); PI-3K-d (1.61 ± 0.34); PI-3K-g (0.06 ± 0.04). B. Chondrocytes in monolayer were pre-treated with inhibitor (5 mM LYor 10 mM A66, TGX, CAL, or AS) for 30 min followed
by 30 min stimulation with 100 ng/ml IGF-1 or 10 ng/ml IL-1b þ 10 ng/ml OSM. Representative blots are shown (n ¼ 3 independent experiments using cells from three unique tissue
donors). C. Chondrocytes in monolayer were pre-treated with inhibitors for 30 min followed by overnight stimulation with 10 ng/ml IL-1b þ 10 ng/ml OSM. Representative blots
from MMP blots of conditioned media are shown (n ¼ 3 independent experiments using cells from three unique tissue donors). D. MMP-13 in conditioned media was quantiﬁed by
total MMP-13 ELISA. Data are normalized to amount of MMP-13 stimulated by IL-1b/OSM without inhibitors (set to 100%). Data shown are mean ± SD (n ¼ 3 independent normal
tissue donors). Treatment (mean ± SD): Control (17.99 ± 13.01); IL-1b/OSM (100.0 ± 0.0); LY þ IL-1b/OSM (35.02 ± 8.53); A66 þ IL-1b/OSM (122.3 ± 23.42); TGX þ IL-1b/OSM
(73.99 ± 32.16); CAL þ IL-1b/OSM (74.00 ± 20.07); AS þ IL-1b/OSM (41.38 ± 23.54). Control vs IL-1b/OSM, P ¼ 0.0027; IL-1b/OSM vs LY þ IL-1b/OSM, P ¼ 0.176; IL-1b/OSM vs AS þ IL-
1b/OSM, P ¼ 0.0358.
M.A. Greene, R.F. Loeser / Osteoarthritis and Cartilage 23 (2015) 949e956 955Of note from the present study, IL-1b alone was not sufﬁcient to
phosphorylate Akt or STAT3 while OSM alone was not sufﬁcient to
phosphorylate JNK indicating that the combined effect of these
cytokines on multiple signaling pathways may be responsible for
the observed potent effect of this combination on cartilage matrixFig. 6. Integrated signaling network of key pathways activated by IGF-1, IL-1b, OSM, and
by IGF-1 (green), IL-1b (red), OSM (blue), and IL-1b/OSM (parallel red and blue). Solid lin
stimulus. The dashed line is to indicate that IL-1b by itself does not stimulate Akt phosphory
the relative level of phosphorylation stimulated (e.g., IGF-1 is a strong stimulator of Akt p
signaling network illustrates that while IGF-1 and the combination of IL-1b and OSM shar
differential activation of the JNK and p38 MAP kinases as well as STAT3.destruction7,13. The ﬁndings from this study suggest that targeting
signaling proteins, such as JAK1/2, activated by IL-1b or OSM and
not by IGF-1 would provide a better therapeutic approach to
restoring the balance in anabolic and catabolic activity in cartilage
in order to slow further progression of cartilage loss in OA.IL-1b/OSM. The integrated signaling network is color-coded to track pathways activated
es with arrows indicate pathway activation and kinase phosphorylation by indicated
lation but does when used in combination with OSM. The weight of the lines indicates
hosphorylation and PG synthesis, so those green arrows are weighted heavily). This
e activation of the PI-3K-Akt pathway, they have different downstream effects due to
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